OncoMatch/Clinical Trials/NCT05632562
Multiparametic Metabolic and Hypoxic PET/MRI for Disease Assessment in High Grade Glioma
Is NCT05632562 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies O-(2-[18F]Fluoroethyl)-L-tyrosine, [18F]-FET with PET/MRI for high grade glioma.
Treatment: O-(2-[18F]Fluoroethyl)-L-tyrosine, [18F]-FET with PET/MRI — This feasibility study will assess the clinical potential of a new imaging approach to detect viable high grade glioma (HGG) in pediatric and adult patients after standard of care radiation therapy (RT) with or without concurrent temozolomide (TMZ). Study participants will undergo simultaneous positron emission tomography/magnetic resonance imaging (PET/MRI) with O-(\[2-\[F-18\]fluoroethyl)-L-tyrosine (FET, amino acid transport) and 1H-1-(3-\[F-18\]fluoro-2-hydroxypropyl)-2-nitroimidazole (FMISO, hypoxia) at the time of standard of care imaging after completion of RT. The presence of viable tumor at this time point will be assessed on a per patient basis. Study participants will be followed clinically and with standard of care (SOC) imaging for up to 2 years after completion of PET/MRI to determine the nature of lesions seen on investigational imaging and to obtain patient outcome data. The imaging data will also be used to develop a semi-automated workflow suitable for implementation in clinical trials and standard of care PET/MRI studies.
Check if I qualifyExtracted eligibility criteria
Cancer type
Glioblastoma
Disease stage
Required: Stage III, IV
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: external beam radiation therapy — standard of care
treated with standard of care external beam radiation therapy (RT)
Cannot have received: bevacizumab (bevacizumab)
Use of bevacizumab or an investigational therapeutic drug for any indication within 3 months prior to the imaging study.
Cannot have received: investigational therapeutic drug
Use of bevacizumab or an investigational therapeutic drug for any indication within 3 months prior to the imaging study.
Lab requirements
Kidney function
estimated gfr >= 30 ml/min
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- UAB · Birmingham, Alabama
- UAB · Birmingham, Alabama
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify